Pricing Log in Create free account

BlossomHill Therapeutics, Inc. (BLSM) vs Relmada Therapeutics, Inc. (RLMD)

BlossomHill Therapeutics, Inc. and Relmada Therapeutics, Inc. are both Biotechnology companies. Relmada Therapeutics, Inc. is the larger, with a market value of $455.5M against $394.5M — 1.2× the size. Across the 7 metrics below, Relmada Therapeutics, Inc. leads on 5 and BlossomHill Therapeutics, Inc. on 2.

Valuation

Metric BLSM RLMD Biotechnology median
P/E n/m n/m 10.64
P/S n/m n/m 9.59
P/B n/m 2.32 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA 0.86 n/m 0.65
EV/Sales n/m n/m 9.45
Earnings yield (215.71%) (22.37%) (34.69%)
Free cash flow yield (193.74%) (26.54%) (24.02%)

Profitability

Metric BLSM RLMD Biotechnology median
Gross margin — 0.00% 65.59%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% (55.66%) (51.96%)
Return on assets 0.00% (51.57%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BLSM RLMD Biotechnology median
Revenue growth (TTM) — — 4.59%
EPS growth (last fiscal year) (85.30%) 45.28% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric BLSM RLMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.42 29.52 4.86
Net debt to EBITDA 2.15 1.57 1.01

Dividend

Metric BLSM RLMD Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric BLSM RLMD Biotechnology median
Market cap 394.45m 455.48m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack